Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows
PHVS released positive data on deucrictibant for HAE treatment. Deucrictibant showed significant improvement over placebo with faster symptom relief. Plans for marketing authorization applications to start in 2026. Stock price increased by 12.32%, indicating strong investor interest. Ongoing competition includes treatments from Ionis and KalVista Pharmaceuticals.
View signal analysis